Simona Jakab, MD
Associate Professor of Medicine (Digestive Diseases); Firm Chief, Klatskin Liver Service, Internal Medicine
Research & Publications
Biography
News
Coauthors
Selected Publications
- Letter of the Editor: Survey of attitudes and knowledge of early paracentesis guidelines and performance in providers in the veterans health administration.Barnard Giustini A, Patel A, Cheung R, Nobbe A, Perumalswami P, Johnson R, Jakab S, Patton H, Morgan T, Oleary J, Bajaj J, Rogal S. Letter of the Editor: Survey of attitudes and knowledge of early paracentesis guidelines and performance in providers in the veterans health administration. Liver Transplantation 2024 PMID: 38920367, DOI: 10.1097/lvt.0000000000000426.
- 869 GUT MICROBIOME PROFILE THROUGH MACHINE LEARNING ALGORITHMS CLARIFIES HEPATIC ENCEPHALOPATHY DIAGNOSES IN A MULTI-CENTER CIRRHOSIS COHORTBajaj J, O'Leary J, Jakab S, Chong N, Sikaroodi M, Gillevet P. 869 GUT MICROBIOME PROFILE THROUGH MACHINE LEARNING ALGORITHMS CLARIFIES HEPATIC ENCEPHALOPATHY DIAGNOSES IN A MULTI-CENTER CIRRHOSIS COHORT. Gastroenterology 2024, 166: s-200-s-201. DOI: 10.1016/s0016-5085(24)00954-5.
- Hospital Utilization for Patients With Cirrhosis and Severe Ascites in a Model of Outpatient Paracentesis by Interventional RadiologyAhmed M, Islam M, Gogokhia L, Borz-Baba C, Wakefield D, Jakab S. Hospital Utilization for Patients With Cirrhosis and Severe Ascites in a Model of Outpatient Paracentesis by Interventional Radiology. Cureus 2023, 15: e51397. PMID: 38292997, PMCID: PMC10826452, DOI: 10.7759/cureus.51397.
- Mycophenolate mofetil for drug-induced vanishing bile duct syndrome.Jakab SS, West AB, Meighan DM, Brown RS, Hale WB. Mycophenolate mofetil for drug-induced vanishing bile duct syndrome. World Journal Of Gastroenterology 2007, 13: 6087-9. PMID: 18023105, PMCID: PMC4250896, DOI: 10.3748/wjg.v13.45.6087.
Clinical Trials
Conditions | Study Title |
---|---|
Diseases of the Digestive System - Liver | A Phase 3 Study Evaluating Long-term Efficacy and Safety of Lanifibranor in Adult Patients With (NASH) and Fibrosis 2 (F2)/Fibrosis 3 (F3) Stage of Liver Fibrosis (NATiV3) |
Diseases of the Digestive System - Liver | Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA) (MIRNA) |
Diseases of the Digestive System - Liver | A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASH (VOYAGE) |